Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Cash (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Change in Cash for 5 consecutive years, with $103.7 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 456.35% to $103.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $151.4 million through Dec 2025, up 1224.85% year-over-year, with the annual reading at $151.4 million for FY2025, 1224.85% up from the prior year.
  • Change in Cash hit $103.7 million in Q4 2025 for Krystal Biotech, up from $38.8 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $135.1 million in Q2 2023 to a low of -$72.6 million in Q2 2021.
  • Historically, Change in Cash has averaged $11.4 million across 5 years, with a median of -$14.1 million in 2023.
  • Biggest YoY gain for Change in Cash was 456.35% in 2025; the steepest drop was 5423.75% in 2025.
  • Year by year, Change in Cash stood at $54.6 million in 2021, then crashed by 144.86% to -$24.5 million in 2022, then skyrocketed by 39.15% to -$14.9 million in 2023, then tumbled by 95.14% to -$29.1 million in 2024, then surged by 456.35% to $103.7 million in 2025.
  • Business Quant data shows Change in Cash for KRYS at $103.7 million in Q4 2025, $38.8 million in Q3 2025, and $45.1 million in Q2 2025.